| 451 |
11159798 | A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein. | 2001 Feb |
1 |
| 452 |
11288109 | P-glycoprotein efflux pump expression and activity in Calu-3 cells. | 2001 May |
2 |
| 453 |
11329060 | The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. | 2001 May |
2 |
| 454 |
11392446 | Determinants of paclitaxel uptake, accumulation and retention in solid tumors. | 2001 May |
1 |
| 455 |
11410497 | The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. | 2001 Jun |
1 |
| 456 |
11465412 | P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. | 2001 May |
2 |
| 457 |
11496948 | Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein. | 2001 Jul |
5 |
| 458 |
11504769 | Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. | 2001 Aug 15 |
6 |
| 459 |
11504826 | Kinetics of P-glycoprotein-mediated efflux of paclitaxel. | 2001 Sep |
7 |
| 460 |
11552225 | Pharmacokinetic profiles of doxorubicin in combination with taxanes. | 2001 Aug |
2 |
| 461 |
11564553 | The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. | 2001 Sep |
1 |
| 462 |
11605182 | Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. | 2001 Aug |
1 |
| 463 |
11606389 | The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. | 2001 Oct 15 |
2 |
| 464 |
11606393 | Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. | 2001 Oct 15 |
2 |
| 465 |
11668581 | Abundant expression of the microtubule-associated protein, ensconsin (E-MAP-115), alters the cellular response to Taxol. | 2001 Jul |
1 |
| 466 |
11710832 | Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. | 2001 Oct 19 |
2 |
| 467 |
11780384 | Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides. | 2001 Sep |
4 |
| 468 |
11891611 | Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. | 2001 |
2 |
| 469 |
11925927 | Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. | 2001 Dec |
2 |
| 470 |
10601617 | Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates. | 2000 Jan-Feb |
3 |
| 471 |
10741911 | Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. | 2000 Mar |
1 |
| 472 |
10745175 | Strength and specificity of different gene promoters in oral cancer cells. | 2000 Mar |
1 |
| 473 |
10755318 | N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. | 2000 |
1 |
| 474 |
10803921 | Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. | 2000 |
1 |
| 475 |
10872505 | Detection of recombinant P-glycoprotein in multidrug resistant cultured cells. | 2000 Feb |
2 |
| 476 |
10912951 | Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. | 2000 Jun |
2 |
| 477 |
10918072 | MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. | 2000 Aug 4 |
2 |
| 478 |
11036469 | Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types. | 2000 |
5 |
| 479 |
11052631 | Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel. | 2000 |
1 |
| 480 |
11104578 | Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. | 2000 Dec |
1 |
| 481 |
11106232 | Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer. | 2000 Nov |
2 |
| 482 |
11205313 | PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant. | 2000 Nov-Dec |
5 |
| 483 |
11218898 | [Study of mdr1 antisense oligodeoxynucleotides on reversal of multidrug resistance in ovarian carcinoma cell line SKOV3]. | 2000 Nov |
1 |
| 484 |
11809106 | [The expression of multiple drug resistance associated genes in ovarian cancer]. | 2000 Feb |
1 |
| 485 |
11876985 | [Exploration of factors increasing transfer efficiency of retroviral mediated multidrug resistance gene (mdr1) into human CD(34)(+) cells]. | 2000 May |
2 |
| 486 |
9864431 | The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. | 1999 Jan-Feb |
3 |
| 487 |
10100591 | The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells. | 1999 |
1 |
| 488 |
10193934 | Effects of paclitaxel on the growth of normal, polyposis, and cancerous human colonic epithelial cells. | 1999 Apr 1 |
2 |
| 489 |
10430060 | Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. | 1999 Jul |
5 |
| 490 |
10453729 | A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. | 1999 |
1 |
| 491 |
10576649 | The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells. | 1999 Nov |
3 |
| 492 |
10602425 | Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. | 1999 Dec |
1 |
| 493 |
11498350 | Molecular mechanisms of resistance to taxanes and therapeutic implications. | 1999 Dec |
1 |
| 494 |
11550305 | Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. | 1999 Apr |
1 |
| 495 |
9510502 | Reversal of multidrug resistance by novel verapamil analogs in cancer cells. | 1998 Feb |
2 |
| 496 |
9516927 | Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. | 1998 Feb |
6 |
| 497 |
9531522 | Taxol transport by human intestinal epithelial Caco-2 cells. | 1998 Apr |
1 |
| 498 |
9572489 | Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. | 1998 Apr 23 |
3 |
| 499 |
9625436 | The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. | 1998 Mar |
1 |
| 500 |
9738565 | Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. | 1998 Sep |
1 |